Director/PDMR Shareholding (0267F)

TIDMMDST

RNS Number : 0267F

Medicsight Plc

15 April 2011

 
 Press release   15 April 2011 
 

Medicsight PLC

("Medicsight" or "the Company")

Directors Share Holdings

Medicsight PLC (AIM: MDST), an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software to assist in the early detection of disease, has today been notified that on 12 April 2011, Executive Director, Allan Rowley increased his holding in ordinary shares of the Company by 625,000.

The increase has arisen as a result of MGT Capital Investments Inc. (Medicsight's majority shareholder) settling an amount due to Mr Rowley by way of shares in the Company for a nominal value of GBP1.

MGT Capital Investments Inc.'s shareholding in Medicsight has therefore reduced to 54.5%.

Following this increase in holding, the Executive Directors' interests (either directly or indirectly) in ordinary shares are set out below:

 
                 Number of ordinary   Total ordinary       % of issued 
                  shares purchased:          shares:    shared capital 
--------------  -------------------  ---------------  ---------------- 
 Allan Rowley               625,000          707,000             0.45% 
--------------  -------------------  ---------------  ---------------- 
 

- ENDS -

For further information:

 
 Medicsight plc 
 Allan Rowley, CEO                 Tel: [phone] 
                                   www.medicsight.com 
 Daniel Stewart & Co 
 Noelle Greenaway / Oliver Rigby   Tel: [phone] 
                                    6550 
                                   www.danielstewart.co.uk 
 

Media enquiries:

 
 Abchurch 
                                    www.abchurch-group.com 
 Julian Bosdet 
 [e-mail] 
 Adam Michael                       Tel: [phone] 
                                     7708 
 [e-mail] 
 Simone Elviss                      Tel: [phone] 
                                     7728 
 [e-mail] 
 Quincy Allan                       Tel: [phone] 
                                     7710 
 [e-mail] 
 

Notes to editors

Medicsight plc is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD software has been developed using a large and population diverse database of verified patient CT scan data. Medicsight's ColonCAD(TM) software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.

About Computer-Aided Detection

With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations generate as many as 2000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This can be critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful treatment and a positive therapeutic outcome. In addition to supporting individual radiologists CAD also has the potential to help standardise CT interpretation across both individuals and institutions thereby supporting population based screening programmes.

About Medicsight's CAD software

Medicsight's ColonCAD(TM) software uses an advanced CAD algorithm to analyse CT scans of the colon and automatically highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such as small lesions or regions that are hidden from view behind folds in the colon.

ColonCAD can be seamlessly integrated with advanced 3D visualisation platforms of industry-leading imaging equipment partners. The integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data, or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.

Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be validated to the highest possible standard.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSIAMJTMBBBBFB